Wockhardt Share Price
Start SIP in Wockhardt
Start SIPWockhardt Performance
Day Range
- Low 1,263
- High 1,319
52 Week Range
- Low 232
- High 1,319
- Open Price1,315
- Previous Close1,310
- Volume564296
Wockhardt Investment Rating
-
Master Rating:
-
Wockhardt Ltd. is a global pharmaceutical and biotechnology company specializing in the development, manufacturing, and marketing of medicines, vaccines, and biosimilars. It focuses on key therapeutic areas including anti-infectives, cardiology, and diabetes care. Wockhardt has an operating revenue of Rs. 2,893.00 Cr. on a trailing 12-month basis. An annual revenue growth of 4% is not great, Pre-tax margin of -15% needs improvement, ROE of -13% is poor and needs improvement. The company has a reasonable debt to equity of 27%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 17% and 66% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 13% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 36 which is a POOR score indicating inconsistency in earnings, a RS Rating of 96 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 28 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of A is the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 352 | 355 | 288 | 260 | 251 | 291 |
Operating Expenses Qtr Cr | 272 | 401 | 263 | 270 | 256 | 321 |
Operating Profit Qtr Cr | 80 | -46 | 25 | -10 | -5 | -30 |
Depreciation Qtr Cr | 43 | 45 | 43 | 44 | 44 | 45 |
Interest Qtr Cr | 58 | 59 | 61 | 59 | 58 | 58 |
Tax Qtr Cr | 0 | 0 | 0 | 0 | 0 | 10 |
Net Profit Qtr Cr | 6 | -126 | -74 | -107 | -115 | -299 |
Wockhardt Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 16
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹1,111.92
- 50 Day
- ₹1,036.06
- 100 Day
- ₹934.57
- 200 Day
- ₹777.35
- 20 Day
- ₹1,084.96
- 50 Day
- ₹1,042.20
- 100 Day
- ₹932.38
- 200 Day
- ₹733.74
Wockhardt Resistance and Support
Resistance | |
---|---|
First Resistance | 1,333.43 |
Second Resistance | 1,356.92 |
Third Resistance | 1,401.13 |
RSI | 73.74 |
MFI | 79.51 |
MACD Single Line | 37.31 |
MACD | 60.64 |
Support | |
---|---|
First Support | 1,265.73 |
Second Support | 1,221.52 |
Third Supoort | 1,198.03 |
Wockhardt Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 1,462,229 | 66,355,952 | 45.38 |
Week | 904,608 | 41,204,913 | 45.55 |
1 Month | 594,160 | 30,159,547 | 50.76 |
6 Month | 551,270 | 35,132,438 | 63.73 |
Wockhardt Result Highlights
Wockhardt Synopsis
NSE-Medical-Generic Drugs
Wockhardt Ltd. is a leading global pharmaceutical and biotechnology company engaged in the research, development, and manufacturing of a wide range of medicines, vaccines, and biosimilars. The company’s product portfolio spans critical therapeutic areas such as anti-infectives, cardiology, diabetes, respiratory, and pain management. Wockhardt operates state-of-the-art manufacturing and R&D facilities in India, the UK, Ireland, and the US, adhering to international quality standards. With a strong emphasis on innovation, Wockhardt invests significantly in developing novel drug formulations and biotechnology products. The company is committed to improving patient health worldwide through advanced, affordable, and high-quality healthcare solutions.Market Cap | 20,098 |
Sales | 1,255 |
Shares in Float | 7.36 |
No of funds | 141 |
Yield |
Book Value | 11.22 |
U/D Vol ratio | 2.1 |
LTDebt / Equity | 50 |
Alpha | 0.58 |
Beta | 1.34 |
Wockhardt Shareholding Pattern
Owner Name | Sep-24 | Jun-24 | Mar-24 | Dec-23 |
---|---|---|---|---|
Promoters | 51.99% | 51.99% | 51.6% | 54.93% |
Mutual Funds | 2.95% | 2.91% | 3.11% | 0.09% |
Insurance Companies | ||||
Foreign Portfolio Investors | 6.7% | 5.94% | 5.49% | 4.18% |
Financial Institutions/ Banks | ||||
Individual Investors | 29.02% | 30.18% | 29.93% | 32.94% |
Others | 9.34% | 8.98% | 9.87% | 7.86% |
Wockhardt Management
Name | Designation |
---|---|
Dr. Habil Khorakiwala | Founder Chairman |
Dr. Murtaza Khorakiwala | Managing Director |
Dr. Huzaifa Khorakiwala | Executive Director |
Ms. Zahabiya Khorakiwala | Non Executive Director |
Mrs. Tasneem Mehta | Independent Director |
Mr. Vinesh Kumar Jairath | Independent Director |
Mr. Akhilesh Gupta | Independent Director |
Ms. Amelia Fernandes | Independent Director |
Mr. Ahmad Javed | Independent Director |
Wockhardt Forecast
Price Estimates
Wockhardt Corporate Action
Date | Purpose | Remarks |
---|---|---|
2024-08-09 | Quarterly Results | |
2024-05-28 | Audited Results | |
2024-03-26 | Others | Inter alia, to consider and determine the issue price of Equity Shares to be issued pursuant to the Issue, including any discount, not more than 5%, on the floor price. issue of equity shares of Rs. 5/- each in the ratio of 3:10 @ premium of Rs. 220/-. |
2024-02-14 | Quarterly Results | |
2023-11-14 | Quarterly Results |
Wockhardt FAQs
What is Share Price of Wockhardt ?
Wockhardt share price is ₹1,300 As on 05 November, 2024 | 12:40
What is the Market Cap of Wockhardt ?
The Market Cap of Wockhardt is ₹19957.2 Cr As on 05 November, 2024 | 12:40
What is the P/E ratio of Wockhardt ?
The P/E ratio of Wockhardt is -58.2 As on 05 November, 2024 | 12:40
What is the PB ratio of Wockhardt ?
The PB ratio of Wockhardt is 5.5 As on 05 November, 2024 | 12:40
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.